Keppra: Revision history

12 November 2024

• curprev 10:5810:58, 12 November 2024‎ 69.163.248.232 talk‎ 1,842 bytes −30‎ No edit summary undo Tag: Manual revert
• curprev 10:2210:22, 12 November 2024‎ 69.163.248.232 talk‎ 1,872 bytes +10‎ Updated category= to treatment_category= in TreatmentInfo template undo
• curprev 10:1610:16, 12 November 2024‎ 69.163.248.232 talk‎ 1,862 bytes +10‎ Updated category= to treatment_category= in TreatmentInfo template undo
• curprev 10:1510:15, 12 November 2024‎ 69.163.248.232 talk‎ 1,852 bytes +10‎ Updated category= to treatment_category= in TreatmentInfo template undo
• curprev 10:1310:13, 12 November 2024‎ 69.163.248.232 talk‎ 1,842 bytes +10‎ Updated category= to treatment_category= in TreatmentInfo template undo

27 March 2024

• curprev 08:5108:51, 27 March 2024‎ Lazy talk contribs‎ 1,832 bytes +475‎ No edit summary undo

19 March 2024

• curprev 08:3508:35, 19 March 2024‎ Lazy talk contribs‎ 1,357 bytes +1,357‎ Created page with "{{TreatmentInfo |drug_name=Keppra (Levetiracetam) |FDA_approval=Yes (as an anti-seizure medication, 1999) |used_for=Seizure prevention in brain tumor patients, potential sensitizer for glioblastoma cells to temozolomide chemotherapy |clinical_trial_phase=Retrospective studies and laboratory research |common_side_effects=Common side effects associated with Keppra include fatigue, dizziness, and mood changes, but it is generally well-tolerated in the context of brain tumor..."